<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881644</url>
  </required_header>
  <id_info>
    <org_study_id>MigRosExperiment</org_study_id>
    <nct_id>NCT03881644</nct_id>
  </id_info>
  <brief_title>PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine</brief_title>
  <official_title>Investigation of PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to investigate the incidence of headache, migraine attacks and flushing after
      pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with
      sumatriptan in patients with migraine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pituitary adenylate cyclase-activating peptide-38 (PACAP38) plays a role in migraine
      pathophysiology. Infusions of PACAP38 can trigger migraine-like attacks in some migraine
      patients and will induce flushing in all patients. We are investigating whether treatment
      with sumatriptan has an effect on the PACAP38-induced flushing and on whether headache and
      migraine is induced.

      The purpose of this study is to investigate PACAP38-induced headache and migraine in patients
      with migraine who have been treated with either sumatriptan or placebo using
      purpose-developed standardized interview. The study will be conducted with a double-blind,
      placebo-controlled crossover study design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2018</start_date>
  <completion_date type="Actual">December 7, 2019</completion_date>
  <primary_completion_date type="Actual">December 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of migraine</measure>
    <time_frame>From 0 to 12 hours after infusion</time_frame>
    <description>Incidence of migraine after PACAP38-infusion will be estimated through a standardized interview based on the international headache classification for migraine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Sumatriptan</measure>
    <time_frame>From 0 to 12 hours after infusion</time_frame>
    <description>Severity of PACAP38-induced headache and migraine after pretreatment with sumatriptan in migraine patients measured by numerical rating scale for pain from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of flushing</measure>
    <time_frame>From 0 to 4 hours after infusion</time_frame>
    <description>Facial skin blood flow (flushing) will be measured by laser doppler flowmetry to evaluate the severity of PACAP38-induced flushing with and without sumatriptan-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial temperature</measure>
    <time_frame>From 0 to 4 hours after infusion</time_frame>
    <description>PACAP38-induced temperature changes with and without sumatriptan-treatment measured by infrared thermography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Superficial temporal artery diameter</measure>
    <time_frame>From 0 to 4 hours after infusion</time_frame>
    <description>Superficial temporal artery diameter after PACAP38 with and without sumatriptan-treatment measured by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of headache</measure>
    <time_frame>From 0 to 12 hours after infusion</time_frame>
    <description>Severity of PACAP38-induced headache will be rated on a numerical rating scale for pain from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Migraine Without Aura</condition>
  <arm_group>
    <arm_group_label>PACAP38 + Imigran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins
AND
Imigran infusion (0.4 mg/min) for 10 mins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PACAP38 + Isotonic Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins
AND
Isotonic saline for 10 mins (placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imigran</intervention_name>
    <description>All patients will undergo this intervention on one of two study days</description>
    <arm_group_label>PACAP38 + Imigran</arm_group_label>
    <other_name>Sumatriptan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isotonic Saline</intervention_name>
    <description>All patients will undergo this intervention on one of two study days</description>
    <arm_group_label>PACAP38 + Isotonic Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pituitary adenylate cyclase-activating peptide-38</intervention_name>
    <description>All patients will undergo this intervention on both study days</description>
    <arm_group_label>PACAP38 + Imigran</arm_group_label>
    <arm_group_label>PACAP38 + Isotonic Saline</arm_group_label>
    <other_name>PACAP38</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of migraine, according to IHS criteria

          -  weight between 50 - 100 kilograms

          -  women in fertile age must not be pregnant and must use adequate contraception

        Exclusion Criteria:

          -  migraine more than 5 days per month in average over the past year

          -  any primary headache other than migraine, apart from tension-type headache which must
             be less than 5 days per month

          -  headache &lt; 48 hours before experimental day

          -  migraine &lt; 72 hours before each experimental day

          -  daily / frequent use of any medication apart from contraceptive medication

          -  use of any drug less than 5 times the half-life of the drug at the time of the
             experiment

          -  women who are pregnant or breast-feeding at the time of the experiment

          -  anamnestic or clinical signs of hypertension (systolic blood pressure &gt; 150 mmHg
             and/or

          -  diastolic blood pressure &gt; 100 mmHg) or hypotension (systolic blood pressure &lt; 90 mmHg
             and/or diastolic blood pressure &lt; 50 mmHg)

          -  anamnestic or clinical signs of mental illness, or abuse of alcohol / drugs

          -  patients with glaucoma or prostate hyperplasia

          -  anamnestic or clinical symptoms of any sort that the investigating doctor deemed unfit
             for participating in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Messoud Ashina, MD,PhD,DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DanishHC</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Nita Katarina Frifelt Wienholtz</investigator_full_name>
    <investigator_title>Principal Investigator, Medical Doctor, PhD Student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Flushing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Pituitary Adenylate Cyclase-Activating Polypeptide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

